Celgene Acquisition Investor Information

Transaction Update

​​​​November 20, 2019

Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
Press Release​​​​​

​​​​November 15, 2019

Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
Press Release​​​​​

​​​​August 26, 2019

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
Press Release​​​​​

​​​​July 29, 2019

Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
Press Release​​​​​

​​​​June 24, 2019

Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
Press Release​​​​​

​​​​June 5, 2019

Bristol-Myers Squibb Announces Post-Closing Leadership Team
Press Release​​​​​

​​​​April 12, 2019

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Press Release​​​​​

​​​​March 29, 2019

Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
Press Release​​​​​

​​​​March 29, 2019

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
Press Release​​​​​

​​​​March 25, 2019

Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials
Press Release​​​​​
​​​​​​​​Letter to Shareholders​​​
Investor Presentation​​​​​
Fact Sheet​​​

​​​​March 19, 2019

Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene​​
​​​​​​​​​​​Press Release​​​
Investor Presentation​​​​​

​​​​March 6, 2019

Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene
​​​Press Release​​​
Letter to Shareholders​​​
Investor Presentation​​​

​​​​February 28, 2019

Bristol-Myers Squibb Issues Statement in Response to Starboard’s Letter 
​​​Press Release​​​​

​​​​February 22, 2019

Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene 
​​​Press Release​​​

​​​​February 20, 2019

Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene 
​​​Press Release​​​​​
Investor Presentation​​​​

​​​​January 3, 2019

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
​​​Press Release​​
Investor Presentation​

Acquisition FAQs for Celgene Shareholders

Frequently asked questions about Celgene shares and CVRs.

Learn More

Other Information

Achieving Our Vision Through Leading Scientific Innovation

Achieving Our Vision Through Leading Scientific Innovation

The new company is united by one vision for the future, and we are already making tangible progress toward achieving it.

Best of Biopharma

Information on the Bristol-Myers Squibb and Celgene Transaction

Learn more about Bristol-Myers Squibb’s planned acquisition of Celgene.